一次情報の記録
Kairos Pharma reported positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) plus apalutamide in mCRPC. The interim analysis showed a statistically significant improvement in progression-free survival compared to apalutamide alone. This is the first announcement of these results.
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company’s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mec